Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 27

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

338

HTML

1588

Figures (1-2)

132

Tables (1-3)

131

Sum=2189

Jul 21, 2011 (publication date) through May 6, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jul 21, 2011; 17(27): 3242-3247
Published online Jul 21, 2011. doi: 10.3748/wjg.v17.i27.3242

Table 1 Baseline demographic and clinical characteristics of patient population

	Treatment group	Placebo group
No. of patients	98	97
Age (yr, mean ± SD)	49.2 ± 14.1	45.5 ± 14.9
Gender (male/female)	47/51	42/55
Total scores of symptoms before treatment (mean ± SD)	9.0 ± 2.8	8.4 ± 2.6

Table 2 Total efficacy of Helicobacter pylori eradication therapy in functional dyspepsia patients with Helicobacter pylori infection n (%)

	Group	n	Clinical recovery	Significant improvement	Improvement	Invalidation	Total effective rates
PP	Treatment group
	Patients with successful H. pylori eradication	72	11 (15.3)	21 (29.1)	30 (41.7)	10 (13.9)	32 (44.4)^a
	Patients receiving H. pylori eradication therapy	84	12 (14.3)	24 (28.6)	33 (39.3)	15 (17.8)	36 (42.9)^a
	Placebo group	89	3 (3.4)	16 (18.0)	34 (38.2)	36 (40.4)	19 (21.4)
ITT	Treatment group	98	12 (12.2)	24 (24.5)	33 (33.7)	29 (29.6)	36 (36.7)^a
	Placebo group	97	3 (3.1)	16 (16.5)	34 (35.1)	44 (45.4)	19 (19.6)

^aP < 0.05 vs the placebo group. H. pylori: Helicobacter pylori; PP: Per-protocol; ITT: Intent-to-treat.

Table 3 Respective efficacy for six common symptoms in functional dyspepsia patients n (%)

	Group	n	Effective rates
	Group	n	Postprandial distress syndrome				Epigastric pain syndrome
			Postprandial fullness	Early satiety	Nausea	Belching	Epigastric pain	Epigastric burning
PP	Treatment group
	Patients with successful H. pylori eradication	72	23 (46.0)	18 (36.0)	21 (52.5)	15 (33.3)	44 (77.2)^a	41 (82.0)^a
	Patients receiving H. pylori eradication therapy	84	24 (41.4)	19 (33.3)	23 (50.0)	16 (31.4)	48 (73.8)^a	46 (80.7)^a
	Placebo group	89	24 (39.3)	16 (27.1)	18 (39.1)	16 (31.4)	26 (38.2)	21 (38.2)
ITT	Treatment group	98	24 (34.8)	19 (27.9)	23 (41.1)	16 (26.7)	48 (60.8)^a	46 (65.7)^a
	Placebo group	97	24 (34.8)	16 (23.9)	18 (35.3)	16 (27.1)	26 (33.3)	21 (31.8)

^aP < 0.05 vs the placebo group. H. pylori: Helicobacter pylori; PP: Per-protocol; ITT: Intent-to-treat.

Citation: Lan L, Yu J, Chen YL, Zhong YL, Zhang H, Jia CH, Yuan Y, Liu BW. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17(27): 3242-3247
URL: https://www.wjgnet.com/1007-9327/full/v17/i27/3242.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i27.3242